Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. You look at survival for patients with ...
Stage 1 multiple myeloma features low beta-2 microglobulin, high albumin, and no organ damage, often detected incidentally. Diagnosis involves blood, urine, imaging tests, and bone marrow biopsy to ...
Bristol Myers Squibb (BMY) announced on Tuesday that a late-stage study evaluating Iberdomide in patients with relapsed or refractory multiple myeloma demonstrated a statistically significant ...
Bristol Myers Squibb BMY announced positive data from the late-stage study on iberdomide in patients with relapsed or refractory multiple myeloma (RRMM). The phase III EXCALIBER-RRMM (NCT04975997) is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback